Table 3.
Correlations between CD5 expression, CD43 expression, and CD5/CD43 coexpression and clinicopathological factors of DLBCL patients
| Characteristics | CD5, number (%) | CD43, number (%) | CD5/CD43, number (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | P | Positive | Negative | P | Double Positive | Others | P | |
| Overall | 18 (9.0) | 182 (91.0) | 54 (27.0) | 146 (73.0) | 10 (5.0) | 190 (95.0) | |||
| Age (years) | |||||||||
| >60 | 12 (66.7) | 106 (58.2) | 0.045 | 23 (42.6) | 95 (65.1) | 0.004 | 7 (70.0) | 111 (58.4) | 0.047 |
| ≤60 | 6 (33.3) | 76 (41.8) | 31 (57.4) | 51 (34.9) | 3 (30.0) | 79 (41.6) | |||
| Sex | |||||||||
| Male | 11 (61.1) | 98 (53.8) | 0.555 | 33 (61.1) | 76 (52.1) | 0.254 | 9 (90.0) | 100 (52.6) | 0.021 |
| Female | 7 (38.9) | 84 (46.2) | 21 (38.9) | 70 (47.9) | 1 (10.0) | 90 (47.4) | |||
| Ann Arbor stage | |||||||||
| I‐II | 8 (44.4) | 108 (59.3) | 0.222 | 28 (51.9) | 88 (60.3) | 0.284 | 4 (40.0) | 112 (58.9) | 0.237 |
| III‐IV | 10 (55.6) | 74 (40.7) | 26 (48.1) | 58 (39.7) | 6 (60.0) | 78 (41.1) | |||
| ECOG PS | |||||||||
| 0‐1 | 13 (72.2) | 145 (79.7) | 0.459 | 38 (70.4) | 120 (82.2) | 0.068 | 6 (60.0) | 152 (80.0) | 0.130 |
| ≥2 | 5 (27.8) | 37 (20.3) | 16 (29.6) | 26 (17.8) | 4 (40.0) | 38 (20.0) | |||
| LDH level | |||||||||
| Normal | 6 (33.3) | 69 (37.9) | 0.702 | 13 (24.1) | 62 (42.5) | 0.017 | 2 (20.0) | 73 (38.4) | 0.499 |
| Elevated | 12 (66.7) | 113 (62.1) | 41 (75.9) | 84 (57.5) | 8 (80.0) | 117 (61.6) | |||
| Extranodal involvement | |||||||||
| <2 | 6 (33.3) | 137 (79.1) | 0.006 | 25 (46.3) | 118 (80.8) | 0.062 | 3 (30.0) | 148 (77.9) | 0.019 |
| ≥2 | 12 (66.7) | 45 (20.9) | 29 (53.7) | 28 (19.2) | 7 (70.0) | 42 (22.1) | |||
| B symptoms | |||||||||
| Yes | 8 (44.4) | 78 (42.9) | 0.897 | 30 (55.6) | 56 (38.4) | 0.029 | 5 (50.0) | 109 (57.4) | 0.646 |
| No | 10 (55.6) | 104 (57.1) | 24 (44.4) | 90 (61.6) | 5 (50.0) | 81 (42.6) | |||
| Bulky tumora | |||||||||
| Yes | 6 (33.3) | 33 (18.1) | 0.120 | 15 (27.8) | 24 (16.4) | 0.072 | 6 (60.0) | 155 (81.6) | 0.093 |
| No | 12 (66.7) | 149 (81.9) | 39 (72.2) | 122 (83.6) | 4 (40.0) | 35 (18.4) | |||
| IPI | |||||||||
| 0‐2 | 10 (55.6) | 133 (73.1) | 0.116 | 36 (66.7) | 107 (73.3) | 0.357 | 4 (40.0) | 139 (73.2) | 0.024 |
| 3‐5 | 8 (44.4) | 49 (26.9) | 18 (33.3) | 39 (26.7) | 6 (60.0) | 51 (26.8) | |||
| GC phenotype | |||||||||
| GC type | 1 (5.6) | 66 (36.3) | 0.008 | 8 (14.8) | 59 (40.4) | 0.001 | 0 (0.0) | 67 (35.3) | 0.021 |
| Non‐GC type | 17 (94.4) | 116 (63.7) | 46 (85.2) | 87 (59.6) | 10 (100.0) | 123 (64.7) | |||
| Ki‐67 | |||||||||
| <80% | 7 (38.9) | 110 (60.4) | 0.085 | 26 (48.1) | 91 (62.3) | 0.077 | 1 (10.0) | 116 (61.1) | 0.002 |
| ≥80% | 11 (61.1%) | 72 (39.6) | 28 (51.9) | 55 (37.7) | 9 (90.0) | 74 (38.9) | |||
| Treatment | |||||||||
| CHOP | 8 (44.4) | 110 (60.4) | 0.188 | 27 (50.0) | 91 (62.3) | 0.116 | 4 (40.0) | 114 (60.0) | 0.210 |
| R‐CHOP | 10 (55.6) | 72 (39.6) | 27 (50.0) | 55 (37.7) | 6 (60.0) | 76 (40.0) | |||
| Response (%) | |||||||||
| CR | 4 (22.2) | 78 (42.9) | 0.090 | 21 (38.9) | 61 (41.8) | 0.712 | 2 (20.0) | 80 (42.1) | 0.166 |
| PR SD, PD | 14 (77.8) | 104 (57.1) | 33 (61.1) | 85 (58.2) | 8 (80.0) | 110 (57.9) | |||
CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; CR, complete remission; ECOG, Eastern Cooperative Oncology Group; GC, germinal center; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PD, progressive disease; PR, partial remission; PS, performance status; R‐CHOP, rituximab CHOP; SD, stable disease.
a
Bulky tumor means the maximum diameter of the tumor is more than 7.5 cm.